1. Trends in viral hepatitis liver-related morbidity and mortality in New South Wales, AustraliaResearch in context
- Author
-
Shane Tillakeratne, Sallie-Anne Pearson, Maryam Alavi, Behzad Hajarizadeh, Marianne Martinello, Matthew Law, Jacob George, Janaki Amin, Gail Matthews, Jason Grebely, Gregory J. Dore, and Heather Valerio
- Subjects
DC ,HCC ,Hepatitis B ,Hepatitis C ,Mortality ,Liver disease ,Public aspects of medicine ,RA1-1270 - Abstract
Summary: Background: Monitoring hepatitis B virus (HBV) and hepatitis C virus (HCV) liver-related morbidity and mortality is key to evaluate progress towards elimination targets. Methods: HBV and HCV notifications in NSW, Australia (1995–2022) were linked to hospital and mortality records. Temporal trends in decompensated cirrhosis (DC), hepatocellular carcinoma (HCC), and mortality were evaluated among people notified for HBV and HCV. Segmented Poisson regression models were used to assess the impact of the viral hepatitis elimination era (1 January 2015–31 December 2022) on advanced liver disease and mortality. Findings: During 1995–2022, there were 64,865 people with an HBV notification and 112,277 people with an HCV notification in NSW. Between 2002 and 2022, there were significant reductions in age-adjusted HBV- and HCV-related DC, HCC, and liver-related mortality. Among those with HBV, age-standardised incidence per 1000 person-years (py) in 2002, 2015, and 2022 was 3.08, 1.47, and 1.16 for DC (p
- Published
- 2024
- Full Text
- View/download PDF